secwatch.observer — SEC 8-K summary
======================================

Issuer:     Azenta, Inc. (AZTA)
CIK:        0000933974
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001437749-24-024893
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Azenta Q3 revenue $173M (+4% YoY); non-GAAP EPS $0.16 beat; FY revenue guidance cut but EBITDA margin expansion raised
--------------------------------------------------------------------------------

- Q3 revenue $173M, up 4% YoY, organic growth 5%. Sample Mgmt Solutions $81M (+7%), Multiomics $64M (flat), B Medical $29M (+7%).
- GAAP diluted EPS from continuing ops -$0.12; non-GAAP diluted EPS $0.16 vs $0.13 prior year. Adjusted EBITDA $18M, margin 10.3% (+260bps YoY).
- FY2024 revenue guidance lowered to $652-658M (organic down 1-2%); adjusted EBITDA margin expansion ~300bps; non-GAAP EPS guidance raised to $0.30-$0.36.
- Repurchased 4.2M shares for $225.9M in Q3; expects to complete remaining $1.5B authorization by Oct 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/933974/000143774924024893/0001437749-24-024893-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/933974/000143774924024893/azta20240603_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-024893

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer